SciGen receives approval from Australian Register of Therapeutic Goods, for Nemera’s reusable pen injector, for its human growth hormone.
SciTropin A™ Pen is a state-of-the-art pen injector device manufactured by Nemera. It was included in the ARTG in February 2022 opening the way for the device to be distributed for patients in Australia.
“This approval reinforces SciGen’s commitment to provide patients with a safe and effective way of drug self-administration. It will further help improve patient compliance to the SciTropin A therapy as a similar pen technology had demonstrated benefits to patients on insulin therapy.” said Marcus Poh, Marketing Director for Global Direct Markets at SciGen Pte. Ltd.
Based on Nemera’s proprietary PENDURA AD development platform SciTropin A™ Pen device will be available in three different versions depending on the type of somatropin cartridge used by the patient.
SciTropin A™ Pen is a reusable, spring-assisted device dedicated to the administration of SciTropin A™ – the growth hormone distributed by SciGen.
Some of the features of SciTropin A™ Pen device include automatic & precise drug delivery, firm hand placement thanks to clear signalization and lateral positioning of the button. Together, these contribute to highest safety and comfort for patients.
“We are thrilled to partner with SciGen to bring the SciTropin A™ Pen device to patients in Australia. This follows successful launches in Korea, Hong Kong and Philippines” said Radoslaw Romanczuk, Pen Platform Business Development Director at Nemera.
At Nemera, we design and manufacture devices that maximize treatment efficacy and partner with our customers in the best possible way to ultimately bring high-quality and safe treatment solutions to patients. Our partnership with SciGen further strengthens our commitment to bringing superior value to customers and patients.
About Human Growth Hormone:
Human Growth Hormone is intended for the long-term treatment of children (above three years of age) with, growth disturbance due to insufficient secretion of pituitary growth hormone, growth disturbance associated with gonadal dysgenesis (Turner syndrome) and growth disturbance associated with chronic renal insufficiency.
To download the Press Release: Click here
SciGen Pte Ltd. is the global commercial arm of Yifan Pharmaceutical Co. Ltd, an integrated pharmaceutical company engaged in R&D, production and commercialization of API and finished dosage forms. SciGen has commercialized several biotech products, namely Gensulin®/SciLin®, SciTropin A™ and Zometa® . In addition to this, we will be commercialising pipeline assets in diabetology and oncology. Our key focus therapy areas are in endocrinology, oncology, anti-infectives, immunology and hepatology.
As a world-leading drug delivery device solutions provider, our purpose of putting patients first enables us to design and manufacture devices that maximize treatment efficacy.
We are a holistic partner and help our customers succeed in the sprint to market of their combination products. From early device strategy to state-of-the-art manufacturing, we’re committed to the highest quality standards.
Agile and open-minded, we work with our customers as colleagues. Together, we go the extra mile to fulfill our mission.